Entrada Therapeutics (TRDA) Return on Invested Capital (2023 - 2025)
Historic Return on Invested Capital for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 0.33%.
- Entrada Therapeutics' Return on Invested Capital fell 4300.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year decrease of 4300.0%. This contributed to the annual value of 0.14% for FY2024, which is 1300.0% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' Return on Invested Capital is 0.33%, which was down 4300.0% from 0.23% recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Return on Invested Capital registered a high of 0.25% during Q2 2024, and its lowest value of 0.43% during Q2 2023.
- Its 3-year average for Return on Invested Capital is 0.09%, with a median of 0.01% in 2023.
- In the last 5 years, Entrada Therapeutics' Return on Invested Capital soared by 6800bps in 2024 and then tumbled by -4800bps in 2025.
- Quarter analysis of 3 years shows Entrada Therapeutics' Return on Invested Capital stood at 0.01% in 2023, then soared by 1425bps to 0.11% in 2024, then crashed by -407bps to 0.33% in 2025.
- Its last three reported values are 0.33% in Q3 2025, 0.23% for Q2 2025, and 0.01% during Q1 2025.